Faricimab: expanding horizon beyond VEGF

Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67–81. Article CAS Google Scholar Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60. Article CAS Google Scholar Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–8. Article CAS Google Scholar Benest AV, Kruse K, Savant S, Thomas M, Laib AM, Loos EK, et al. Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS ONE. 2013;8:e70459. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA. 2011;108:11187–92. Article CAS Google Scholar Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CMG, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265–88. Article CAS Google Scholar Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, et al. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods. 2019;154:21–31. Article CAS Google Scholar Iwata D, von Leithner PL, Ng YSE, Hartmann G, Shima DT. Anti-VEGF/Ang2 bi-specific antibody ameliorates endotoxin-induced uveitis in mice. Invest Ophthalmol Vis Sci. 2014;55:2354. Chakravarthy U, Bailey C, Brown D, Campochiaro P, Chittum M, Csaky K, et al. Phase I trial of anti–vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration. Ophthalmol Retina. 2017;1:474–85. Article Google Scholar Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema. Ophthalmology. 2019;126:1155–1170. Khanani AM, et al. Simultaneous inhibition of VEGF and Ang-2 with faricimab in neovascular AMD: STAIRWAY phase 2 results. Presented at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting; 26 Oct 2018; Chicago, United States. ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab (RO6867461) in participants with diabetic macular edema. https://clinicaltrials.gov/ct2/show/NCT03622593 . Accessed 15 Jul 2019. ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab (RO6867461) in participants with diabetic macular edema (YOSEMITE). https://clinicaltrials.gov/ct2/show/NCT03622580 . Accessed 15 Jul 2019. ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (TENAYA). https://clinicaltrials.gov/ct2/show/NCT03823287 . Accessed 15 Jul 2019. ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (LUCERNE). https://clinicaltrials.gov/ct2/show/NCT03823300 . Accessed 15 Jul 2019. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85. Article CAS Google Scholar Boyer DS. Intravitreal nesvacumab+aflibercept in diabetic macular edema: The Phase 2 RUBY Trial. Invest. Ophthalmol. Vis. Sci. 2018;59:3620. Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608. Download references